Shuji Ogino

Shuji Ogino (荻野周史, Ogino Shuji, born April 24, 1968) is a molecular pathological epidemiologist, pathologist and epidemiologist. He is currently Professor of Pathology at Harvard Medical School, Brigham and Women's Hospital and Dana-Farber Cancer Institute, and Professor in the Department of Epidemiology at Harvard T.H. Chan School of Public Health. He has been known for his work on establishing a new discipline, molecular pathological epidemiology (abbreviated as MPE), which represents an interdisciplinary science of molecular pathology and epidemiology.

Education, training, and positions

Ogino graduated from University of Tokyo School of Medicine in 1993, and from University of Tokyo Graduate School of Medicine in 2001. He underwent internship at U.S. Naval Hospital Okinawa in Japan from 1994 to 1995. After coming to the United States, Ogino underwent residency training in anatomic pathology and clinical pathology at Allegheny General Hospital (Drexel University) from 1995 to 1997, and at Case Western Reserve University/University Hospitals Case Medical Center from 1997 to 1999. He underwent fellowship training in molecular pathology at University of Pennsylvania Medical Center from 1999 to 2000. After postdoctoral fellowship at University of Pennsylvania, he joined Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School as Instructor in Pathology in 2001. Ogino was promoted to Assistant Professor in 2004, to Associate Professor in 2008, and he became Professor of the institutes in 2015. He received a Master of Science in Epidemiology degree from Harvard T.H. Chan School of Public Health in 2010, and then subsequently obtained a secondary faculty appointment (Associate Professor) in 2012, promoted to Professor at that school in 2015.

Career in MPE and colorectal cancer research

Ogino proposed that research into molecular pathology with epidemiologic settings should be regarded as a distinct field, and used the term “Molecular Pathological Epidemiology (MPE)” in 2010.[1] Since his proposal, the MPE concept and paradigm have been in widespread use,[2][3][4][5][6][7][8][9][10][11][12] and MPE has been a subject of international conferences such as American Association for Cancer Research (AACR),[13] Society for Epidemiologic Research (SER),[14] and the American Society of Preventive Oncology (ASPO).[15] The MPE approach aims to elucidate etiology of disease at molecular, individual, and population levels, applying molecular pathology to epidemiology. Utilizing tissue pathology resource and data within existing epidemiology studies, he has been publishing a large number of original articles proving the interrelationship between exposure to risk factors (e.g., environmental, dietary, lifestyle and genetic factors) and molecular pathologic signature of disease (e.g., PIK3CA mutation in colorectal cancer) including some of influential papers in the field,[16][17][18][19][20][21][22][23] as well as papers which have developed the concepts of MPE.[24][25][26][27][28][29][30][31] Ogino’s discoveries with the MPE approach include the interaction between aspirin use and PIK3CA mutation in colorectal cancer,[32] and the interaction between endoscopy screening and post-colonoscopy colorectal cancer with CIMP and microsatellite instability MSI.[33] He initiated the International Molecular Pathological Epidemiology (MPE) Meeting Series in 2013, and has been serving as the conference chairperson. Its second and third meetings were held in Boston, in December 2014,[34][35] and May 2016,[36] respectively.

Ogino employed the MPE concept for proposing a paradigm shift in colorectal cancer research. His proposal for a transition from the two-colon concept (the proximal and distal colon)[37] [38] [39] [40] to the colorectal continuum model[41] was supported by an observed linear relationship between the location on the colon and Microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutation frequency from the database analyses of over 1,400 colorectal cancer cases.[42] This colorectal continuum model has been supported by others.[43][44]

Ogino has introduced several new paradigms and research frameworks, including “The GWAS-MPE approach”,[45] “the unique tumor principal”,[46] “the Unique Disease Principle”,[47] “the etiologic field effect model”,[48] and "the integrative lifecourse epidemiology - MPE model",[49] all of which are related to the field of MPE.

Honors and awards

References

  1. ↑ Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-367.
  2. ↑ Curtin K, Slattery ML, Samowitz WS (2011). "CpG island methylation in colorectal cancer: past, present and future". Pathology Research International 2011: 902674. doi:10.4061/2011/902674. PMC 3090226. PMID 21559209.
  3. ↑ Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA (2012). "Cancer classification using the Immunoscore: a worldwide task force". Journal of Translational Medicine 10: 205. doi:10.1186/1479-5876-10-205. PMC 3554496. PMID 23034130.
  4. ↑ Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R, Iacopetta B (August 2012). "Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X". Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc 25 (8): 1055–68. doi:10.1038/modpathol.2012.62. PMID 22522846.
  5. ↑ Koshiol J, Lin SW (July 2012). "Can tissue-based immune markers be used for studying the natural history of cancer?". Annals of Epidemiology 22 (7): 520–30. doi:10.1016/j.annepidem.2012.03.001. PMC 3596808. PMID 22481034.
  6. ↑ Fini L, Grizzi F, Laghi L (2012). Ettarh R, ed. Adaptive and Innate Immunity, Non Clonal Players in Colorectal Cancer Progression. InTech. pp. 323–40. ISBN 9789535100621.
  7. ↑ Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, Zakowski MF, Ladanyi M (November 2012). "Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers". Clinical Cancer Research 18 (22): 6169–77. doi:10.1158/1078-0432.CCR-11-3265. PMC 3500422. PMID 23014527.
  8. ↑ Spitz MR, Caporaso NE, Sellers TA (December 2012). "Integrative cancer epidemiology--the next generation". Cancer Discovery 2 (12): 1087–90. doi:10.1158/2159-8290.CD-12-0424. PMC 3531829. PMID 23230187.
  9. ↑ Shanmuganathan R, Basheer NB, Amirthalingam L, Muthukumar H, Kaliaperumal R, Shanmugam K (January 2013). "Conventional and nanotechniques for DNA methylation profiling". The Journal of Molecular Diagnostics : JMD 15 (1): 17–26. doi:10.1016/j.jmoldx.2012.06.007. PMID 23127612.
  10. ↑ Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M (October 2013). "The CpG island methylator phenotype: what's in a name?". Cancer Research 73 (19): 5858–68. doi:10.1158/0008-5472.CAN-12-4306. PMID 23801749.
  11. ↑ Hagland HR, Søreide K (March 2014). "Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways". Cancer Letters. doi:10.1016/j.canlet.2014.02.026. PMID 24614287.
  12. ↑ Bishehsari F, Mahdavinia M, Vacca M, Malekzadeh R, Mariani-Costantini R (May 2014). "Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention". World Journal of Gastroenterology : WJG 20 (20): 6055–72. doi:10.3748/wjg.v20.i20.6055. PMC 4033445. PMID 24876728.
  13. ↑ Ogino S. Molecular pathological epidemiology (MPE): Overview of its paradigm and wide applicability even without tumor tissue. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Cancer Prev Res (Phila). 2013;6(11 suppl):CN06-1.
  14. ↑ Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium. Am J Epidemiol. 2013;178(9):1350-4.
  15. ↑ Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and Opportunities in International Molecular Cancer Prevention Research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2613-7. doi:10.1158/1055-9965.EPI-14-0848. Epub 2014 Oct 2.
  16. ↑ Chan AT, Ogino S, Fuchs CS. Aspirin use and risk of colorectal cancer according to cyclooxygenase-2 expression. N Engl J Med 2007;356:2131-42.
  17. ↑ Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-658.
  18. ↑ Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-1694. PMC 3087286109
  19. ↑ Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumor microenvironment contributes to innate RAF-inhibitor resistance through HGF secretion. Nature 2012;487:500-504. PMC 3711467
  20. ↑ Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and colorectal cancer incidence risk according to BRAF mutation status. JAMA 2013;309:2563-2571.
  21. ↑ Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson III AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS, for the Alliance for Clinical Trials in Oncology. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013;105:1789-1798.
  22. ↑ Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST, Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 2013;493:106-110. PMC 3536889
  23. ↑ Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS, Ogino S, Markowitz SD, Chan AT. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
  24. ↑ Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology – integrated analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011:8:711-719.
  25. ↑ Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education to integrate pathology and epidemiology: Towards molecular and population-level health science. Am J Epidemiol 2012;176:659-667.
  26. ↑ Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability – Molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol 2012;41:1072-1074.
  27. ↑ Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-628.
  28. ↑ Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E (April 2013). "Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease". Modern Pathology 26(4): 465–84.
  29. ↑ Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013;310:2147-2148.
  30. ↑ Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2014;33:2949-2955.
  31. ↑ Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O’Brien M, Ogino S. Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol 2014;109(8):1205-1214.
  32. ↑ Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-1606.
  33. ↑ Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A, Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S, Chan AT. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-1105.
  34. ↑ The Ogino MPE lab ( http://ogino-mpe-lab.dana-farber.org )
  35. ↑ Ogino S, Campbell PT, Nishihara R, Phipps AI, Beck AH, Sherman ME, Chan AT, Troester MA, Bass AJ, Fitzgerald KC, Irizarry RA, Kelsey KT, Nan H, Peters U, Poole EM, Qian ZR, Tamimi RM, Tchetgen Tchetgen EJ, Tworoger SS, Zhang X, Giovannucci EL, van den Brandt PA, Rosner BA, Wang M, Chatterjee N, Begg CB. Proceedings of The Second International Molecular Pathological Epidemiology (MPE) Meeting. Cancer Causes Control. 2015 May 9. PMID 25956270
  36. ↑ Campbell PT, Rebbeck TR, Nishihara R, Beck AH, Begg CB, Bogdanov AA, Cao Y, Coleman HG, Freeman GJ, Heng YJ, Huttenhower C, Irizarry RA, Kip NS, Michor F, Nevo D, Peters U, Phipps AI, Poole EM, Qian ZR, Quackenbush J, Robins H, Rogan PK, Slattery ML, Smith-Warner SA, Song M, VanderWeele TJ, Xia D, Zabor EC, Zhang X, Wang M, Ogino S. Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 Jan 17. doi:10.1007/s10552-016-0845-z. [Epub ahead of print] Review. PMID 28097472
  37. ↑ Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101:403–8.
  38. ↑ Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88:261–6.
  39. ↑ Carethers JM. One colon lumen but two organs. Gastroenterology. 2011;141:411–2.
  40. ↑ Albuquerque C, Bakker ER, van Veelen W, et al. Colorectal cancers choosing sides. Biochim Biophys Acta. 2011;1816:219–31.
  41. ↑ Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs C, Ogino S. Colorectal cancer: a tale of two sides or a continuum? Gut. 2012 Jun;61(6):794-7.
  42. ↑ Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L, Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854. PMC 3345105
  43. ↑ Jess P, Hansen IO, Gamborg M, Jess T; Danish Colorectal Cancer Group. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013 May 28;3(5).
  44. ↑ Papagiorgis P. Colorectal cancer: dichotomous or continuum model? Perhaps, a combination of both. Gut. 2013 Oct;62(10):1519-20.
  45. ↑ Ogino S, Chan AT, Fuchs CS, Giovannucci E. Gut. 2011 Mar;60(3):397-411. doi:10.1136/gut.2010.217182. Epub 2010 Oct 29. Review. PMID 21036793 Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.
  46. ↑ Ogino S, Fuchs CS, Giovannucci E. Expert Rev Mol Diagn. 2012 Jul;12(6):621-8. doi:10.1586/erm.12.46. Review. PMID 22845482 How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.
  47. ↑ Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt JA, Meissner A, Schernhammer ES, Fuchs CS, Giovannucci E. Mod Pathol. 2013 Apr;26(4):465-84. doi:10.1038/modpathol.2012.214. Epub 2013 Jan 11. Review. PMID 23307060 Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.
  48. ↑ Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28(1):14-29. doi:10.1038/modpathol.2014.81. Epub 2014 Jun 13. PMID 24925058.
  49. ↑ Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and molecular pathological epidemiology. Am J Prev Med 2015;48:116-119.
  50. ↑ The world’s Most Influential Minds:2014 (http://thomsonreuters.com/articles/2014/worlds-most-influential-scientific-minds-2014) Thomson Reuter. Retrieved September 5, 2014.
  51. ↑ http://www.faseb.org/About-FASEB/Who-We-Are/Governance/Board-Ordinary-Committees.aspx Retrieved September 15, 2014.
  52. ↑ http://grantome.com/grant/NIH/R35-CA197735-01
  53. ↑ Highly Cited Researchers 2015 (http://highlycited.com/#ogino)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.